SCHEMBL5609750

SCHEMBL5609750

[CH2]CCC(OC)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.41
SLC6A2 P23975 6/20 0.40
CYP1A2 P05177 4/20 0.40
CYP3A4 P08684 4/20 0.40
CYP2D6 P10635 4/20 0.40
TSHR P16473 3/20 0.40
SLC6A3 Q01959 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40
PMP22 Q01453 2/20 0.39
HRH1 P35367 6/20 0.37
HTR2A P28223 5/20 0.37
CHRM1 P11229 2/20 0.37
ADRA2B P18089 2/20 0.37
HTR2C P28335 2/20 0.37
OPRM1 P35372 2/20 0.37
DRD3 P35462 2/20 0.37
OPRK1 P41145 2/20 0.37
HTR2B P41595 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8691151 0.88 SLC6A4 (0.39) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL1157686 0.83 SLC6A4 (0.39) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL1098807 0.81 AOC3 (0.43) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL10887514 0.80 AOC3 (0.54) SLC6A4SLC6A2TSHRALOX15
SCHEMBL10887906 0.80 AOC3 (0.54) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL8567639 0.80 SLC6A4 (0.39) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL6336591 0.79 HRH1 (0.56) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL14528138 0.79 SLC6A4 (0.41) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL1832901 0.79 TRPA1 (0.48) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL10488795 0.79 HPGD (0.41) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 EP claimed
EP-3688124-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME ExxonMobil Chemical Patents Inc. (US) 2020-08-05 EP claimed
US-10711216-B2 Ester compounds, lubricating oil compositions containing same and processes for making same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-07-14 US claimed
CN-111386331-A Ester compound, lubricating oil composition containing same, and method for producing same 埃克森美孚化学专利公司 2020-07-07 CN claimed
WO-2019067061-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-04-04 WO claimed
US-20190100710-A1 Ester Compounds, Lubricating Oil Compositions Containing Same and Processes for Making Same EXXONMOBIL CHEMICAL PATENTS INC. 2019-04-04 US claimed
EP-3676240-B1 ESTER COMPOUNDS AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-11-01 EP disclosed
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 EP disclosed
CN-111032613-B Ester compound, lubricating oil composition containing the same, and method for producing the same 埃克森美孚化学专利公司 2023-03-28 CN disclosed
EP-3688124-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME ExxonMobil Chemical Patents Inc. (US) 2020-08-05 EP disclosed
US-10711216-B2 Ester compounds, lubricating oil compositions containing same and processes for making same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-07-14 US disclosed
EP-3676240-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME ExxonMobil Chemical Patents Inc. (US) 2020-07-08 EP disclosed
CN-111386331-A Ester compound, lubricating oil composition containing same, and method for producing same 埃克森美孚化学专利公司 2020-07-07 CN disclosed
US-20030018197-A1 Anti-HIV pyrazole derivatives HOFFMANN-LA ROCHE INC. 2003-01-23 US disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed
US-20020107272-A1 Anti-HIV imidazolone derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-08-08 US disclosed
WO-2002042279-A1 IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed
WO-2002030907-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-04-18 WO disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 WO disclosed
EP-1167357-A1 ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 SLC6A4 1463/4885SLC6A2 1593/4885CYP1A2 3228/4885
US-20020107272-A1 Anti-HIV imidazolone derivatives EIF2AK2, IMPDH1, POLR2E SLC6A4 3791/4885SLC6A2 4385/4885CYP1A2 880/4885
US-20030018197-A1 Anti-HIV pyrazole derivatives CYP51A1, TYMP, POLRMT SLC6A4 3992/4885SLC6A2 4607/4885CYP1A2 106/4885
US-10711216-B2 Ester compounds, lubricating oil compositions containing same and processes for making same ELOVL1, NOTUM, ELOVL5 SLC6A4 4293/4885SLC6A2 3650/4885CYP1A2 913/4885
US-20190100710-A1 Ester Compounds, Lubricating Oil Compositions Containing Same and Processes for Making Same ELOVL1, NOTUM, ELOVL5 SLC6A4 4293/4885SLC6A2 3650/4885CYP1A2 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.